리세드론산 또는 그의 염 및 비타민 D를 포함하는 약학 조성물
    12.
    发明公开
    리세드론산 또는 그의 염 및 비타민 D를 포함하는 약학 조성물 无效
    包含升华酸或其盐和维生素D的药物组合物

    公开(公告)号:KR1020130031313A

    公开(公告)日:2013-03-28

    申请号:KR1020130017396

    申请日:2013-02-19

    CPC classification number: A61K9/4858 A61K31/593 A61K31/663

    Abstract: PURPOSE: An oral capsule is provided to suppress bone absorption, to promote calcium salt absorption, and to maintain calcium homeostasis. CONSTITUTION: An oral capsule is prepared by uniformly dispersing risedronic acid or a salt thereof and vitamin D in a mixture solvent containing soybean oil and hydrogenated coconut oil and filling a capsule with the dispersion solution. The mixture solvent further contains 1-3 parts by weight of chrome yellow and lecithin.

    Abstract translation: 目的:提供口服胶囊以抑制骨吸收,促进钙盐吸收,并维持钙稳态。 构成:通过将利塞膦酸或其盐和维生素D均匀分散在含有大豆油和氢化椰子油的混合溶剂中并用分散液填充胶囊来制备口服胶囊。 混合溶剂还含有1-3重量份的铬黄和卵磷脂。

    도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물
    13.
    发明授权
    도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 有权
    包含多瑙酰胺,槲皮酚和嘧啶酮的非线性液体组合物

    公开(公告)号:KR101119610B1

    公开(公告)日:2012-03-06

    申请号:KR1020100121718

    申请日:2010-12-02

    Abstract: PURPOSE: An ophthalmic liquid composition containing dorzolamide or salt thereof, timolol or salt thereof, and brimonidine of salt thereof is provided to minimize irritation and to ensure stability. CONSTITUTION: An ophthalmic liquid composition of surfactant-free and saccharide-free contains 1-3 w/v% of dorzolamide or salt thereof, 0.1-1 w/v% of timolol or salt thereof, 0.1-0.5 w/v% of brimonidine of salt thereof, 1.0-1.5 w/v% of polyvinyl pyrrolidone, 0.2-0.8 w/v% of sodium chloride, 0.3-0.6 w/v% of buffer, preservative, pH adjusting agent, and water.

    Abstract translation: 目的:提供含有多佐胺或其盐,噻吗洛尔或其盐及其溴莫尼啶的眼用液体组合物以使刺激最小化并确保稳定性。 构成:无表面活性剂和无糖的眼用液体组合物含有1-3w / v%的多佐胺或其盐,0.1-1w / v%的噻吗洛尔或其盐,0.1-0.5w / v%的溴莫尼定 的盐,1.0-1.5w / v%的聚乙烯吡咯烷酮,0.2-0.8w / v%的氯化钠,0.3-0.6w / v%的缓冲剂,防腐剂,pH调节剂和水。

    리세드론산 또는 그의 염 및 비타민 D를 포함하는 약학 조성물
    15.
    发明公开
    리세드론산 또는 그의 염 및 비타민 D를 포함하는 약학 조성물 有权
    包含升华酸或其盐和维生素D的药物组合物

    公开(公告)号:KR1020100034294A

    公开(公告)日:2010-04-01

    申请号:KR1020080093344

    申请日:2008-09-23

    CPC classification number: A61K45/06 A61K9/00 A61K31/593 A61K31/663 A61K2300/00

    Abstract: PURPOSE: A pharmaceutical composition containing risedronic acid or salt thereof and vitamin D is provided to simutenously promote absorption of calcium salt and suppress bone absorption. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains risedronic acid or salt thereof and vitamin D. An oral formulation is obtained by tableting mixture of risedronic acid or salt thereof and vitamin D. The mixture additionally contains crospovidone, starch sodium gluconate, disintegrant carboxylmethyl cellulose sodium or alginic acid, lactose, microcrystalline cellulose or corn starch excipient. An oral capsule is manufactured by evenly dispersing risedronic acid or salt thereof and vitamin D in a mixture solvent of soybean oil and hydrogeneated coconut oil, and filling in a capsule.

    Abstract translation: 目的:提供含有利塞膦酸或其盐和维生素D的药物组合物,以同时促进钙盐的吸收和抑制骨吸收。 构成:用于预防或治疗骨质疏松症的药物组合物包含利塞膦酸或其盐和维生素D.通过压制利塞膦酸或其盐和维生素D的混合物获得口服制剂。该混合物另外含有交聚维酮,淀粉葡糖酸钠,崩解剂羧甲基 纤维素钠或藻酸,乳糖,微晶纤维素或玉米淀粉赋形剂。 通过将利塞膦酸或其盐和维生素D均匀分散在大豆油和氢化椰子油的混合溶剂中并填充胶囊来制造口腔胶囊。

    송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물
    16.
    发明授权
    송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물 有权
    一种眼科液体组合物,其包含小牛血液的脱蛋白透析液

    公开(公告)号:KR100671449B1

    公开(公告)日:2007-01-19

    申请号:KR1020050060884

    申请日:2005-07-06

    Abstract: 본 발명은 송아지의 제단백 혈액추출물(deproteinized dialysate of calf's blood) 6.5 ∼ 7.5 w/v%, 히드록시프로필메틸셀룰로오즈 0.05 ∼ 1.0 w/v%, 및 잔량의 멸균 정제수를 포함하는 점안용 액제 조성물을 제공한다.
    본 발명의 점안용 액제 조성물은 낮은 점도 범위를 가짐으로써 종래의 안과용 겔제의 낮은 복약 순응도(compliance)의 문제점을 해결할 수 있을 뿐 아니라 장기간 동안 물리적 및 화학적 안정성을 유지할 수 있다.
    솔코세릴, 점안용 액제

    송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물
    17.
    发明公开
    송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물 有权
    包含CALF血液的脱水化的透明液体组合物

    公开(公告)号:KR1020070005847A

    公开(公告)日:2007-01-10

    申请号:KR1020050060884

    申请日:2005-07-06

    CPC classification number: A61K35/14 A61K9/0048

    Abstract: An ophthalmic liquid composition comprising a deproteinized dialysate of calf's blood is provided to enhance medication compliance of an ophthalmic drug by reducing viscosity, while the liquid type ophthalmic drug maintains its physical and chemical stability for a long period. The ophthalmic liquid composition comprises 6.5-7.5%(w/v) of the deproteinized dialysate of calf's blood, 0.05-1.0%(w/v) of hydroxypropylmethylcellulose and a remaining amount of sterilized water, wherein the composition has viscosity of 0.01-20 mPas; and the composition further comprises additives including stabilizing agent such as sodium edetic acid, buffering agent such as boric acid and borax, preservative such as benzalkonium chloride, methyl rho-hydroxybenzoate and propyl rho-hydroxybenzoate, and pH regulating agent such as hydrochloric acid and sodium hydroxide.

    Abstract translation: 提供包含小牛血液的去蛋白质透析液的眼用液体组合物,以通过降低粘度来提高眼药物的药物依从性,而液体眼药物长时间保持其物理和化学稳定性。 眼用液体组合物包含6.5-7.5%(w / v)的小牛血液脱蛋白透析液,0.05-1.0%(w / v)羟丙基甲基纤维素和剩余量的无菌水,其中组合物的粘度为0.01-20 毫帕·秒; 该组合物还包含添加剂,包括稳定剂如乙酸钠,缓冲剂如硼酸和硼砂,防腐剂如苯扎氯铵,甲基羟基苯甲酸甲酯和对羟基苯甲酸丙酯,以及pH调节剂如盐酸和钠 氢氧化物。

    나노에멀젼 형태의 안과용 조성물
    18.
    发明授权
    나노에멀젼 형태의 안과용 조성물 有权
    纳米乳液形式的光学组成

    公开(公告)号:KR101182115B1

    公开(公告)日:2012-09-12

    申请号:KR1020120048915

    申请日:2012-05-09

    CPC classification number: A61K38/13 A61K9/0048 B82Y5/00

    Abstract: 본 발명은 활성성분으로서 사이클로스포린 A와 함께 특정 오일 및 계면활성제를 수성 매질 중에서 자가유화방법으로 나노에멀젼 형태로 설계한 안과용 조성물을 제공한다. 본 발명에 따른 안과용 조성물은 0.22 ㎛ 필터를 사용한 제균여과가 가능하므로, 제조비용을 낮출 수 있고 또한 생산현장에서 쉽게 적용할 수 있다. 또한, 본 발명의 조성물은 첨가제들의 사용을 최소화하면서, 우수한 안정성을 가진다.

    모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
    20.
    发明公开
    모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물 有权
    用于鼻内给药的药物组合物,其包含糠酸莫米松和盐酸氮卓斯汀

    公开(公告)号:KR1020120058029A

    公开(公告)日:2012-06-07

    申请号:KR1020100119632

    申请日:2010-11-29

    Abstract: PURPOSE: A pharmaceutical composition containing mometasone furoate, azelastine hydrochloride, and thaumatin is provided to enhance drug compliance. CONSTITUTION: A pharmaceutical composition for endonasal adminisration contains 0.01-1.0 w/v% of mometasone furoate and 0.05-1.0 w/v% of azelastine hydrochloride. The pharmaceutical composition also contains 0.1-0.5 w/v% of thaumatin as an agent for relieving bitter taste and stimulation. The pharmaceutical composition further contains 1.0-5.0 w/v% of tackifier, 0.2-0.6 w/v% of buffer, 0.001-0.1 w/v% of surfactant, 5.0-10.0 w/v% of isotonic agent, 0.01-1.0 w/v% of stabilizing agent, and 0.002-0.05 w/v% of preservative in an aqueous medium. The pharmaceutical composition for endonasal administration is formulated in a nasal spray.

    Abstract translation: 目的:提供含有糠酸莫米松,盐酸氮卓斯汀和马齿苋的药物组合物,以提高药物依从性。 构成:用于鼻内给药的药物组合物含有0.01-1.0w / v%的莫米松糠酸盐和0.05-1.0w / v%的盐酸阿斯他汀。 药物组合物还含有0.1-0.5w / v%的作为缓解苦味和刺激的药物的马齿苋。 药物组合物还含有1.0-5.0w / v%的增粘剂,0.2-0.6w / v%的缓冲液,0.001-0.1w / v%的表面活性剂,5.0-10.0w / v%的等渗剂,0.01-1.0w / v%的稳定剂和0.002-0.05w / v%的防腐剂。 用于鼻内给药的药物组合物配制成鼻喷雾剂。

Patent Agency Ranking